3. Adachi Y, et al. Lenvatinib in Combination with Everolimus Demonstrated Enhanced Antiangiogenesis and Antitumor Activity in Human RCC Xenograft Models. AACR 2016; #3264
4. Motzer R, et al. Randomized phase 2 three-arm trial of lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma. The Lancet Oncology 2015;16:1473-82. Available at http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00290-9/abstract . Last accessed: March 2016
5. Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. ACS Med. Chem. Lett 2015;6:89-94
6. Wu P. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discovery Today, July 2015;1-6
7. Cancer Research UK. Available at: http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/everolimus . Accessed: March 2016
8. National Cancer Institute at the National Institute of Health. Available at: http://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq . Accessed: March 2016
CONTACTO: Consultas de los medios de comunicación: Eisai, Cressida Robson/ Ben Speller, +44(0)7908 314 155/+44(0) 7908 409416,Cressida_Robson@eisai.net, Ben_Speller@eisai.net, Tonic LifeCommunications, Alex Davies / Callum Haire, +44 (0)7720 496 472 / +44(0)7867 429 637, Alex.Davies@toniclc.com, Callum.Haire@toniclc.com
